Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
BRM Stock Chart & Stats
€51.56
-€0.23(-0.42%)
At close: 4:00 PM EST
€51.56
-€0.23(-0.42%)
Day’s Range― - ―
52-Week Range€36.60 - €58.20
Previous CloseN/A
Volume2.10K
Average Volume (3M)2.92K
Market Cap
€105.09B
Enterprise Value€157.24B
Total Cash (Recent Filing)€10.67B
Total Debt (Recent Filing)€47.14B
Price to Earnings (P/E)15.6
Beta0.47
Next Earnings
Apr 30, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend Yield5.01%
Share Statistics
EPS (TTM)1.10
Shares Outstanding2,036,473,800
10 Day Avg. Volume2,800
30 Day Avg. Volume2,923
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€54.58Price Target Upside5.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)5.44
Revenue Forecast (FY)€40.74B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInterim data showing meaningful improvement in disease control for the oral CELMoD candidate combined with standard multiple myeloma therapy supports the program as a potential long-term growth driver if pivotal head-to-head trials confirm superiority.
Commercial Performance And Pricing ChangesOne-time US pricing adjustments and reduced rebate liabilities for the leading anticoagulant have boosted revenue expectations and improved cash flow flexibility to support investment in growth products.
Pipeline Breadth And New LaunchesA broad clinical pipeline and more than ten novel medicines in early commercial launches create multiple opportunities to replace revenue from aging brands and sustain longer-term growth.
Bears Say
Generic Competition And Legacy UnderperformanceImminent loss of exclusivity for key medicines and underperformance of some legacy products risk significant revenue erosion, making growth contingent on successful commercialization of new launches.
Regulatory Approval UncertaintyDependence on minimal residual disease as a basis for accelerated approval means conversion to full approval will hinge on future overall survival and progression-free survival data, leaving regulatory and commercial outcomes uncertain.
Safety And TolerabilitySelection of a lower iberdomide dose and prior observations of neutropenia raise concerns that tolerability issues could limit dosing options and reduce the drug's practical market potential.
Bristol-Myers Squibb News
BRM FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €36.60 and its highest was €58.20 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is €105.09B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 30, 2026 which is in 45 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 05, 2026. The company reported €1.101 earnings per share for the quarter, beating the consensus estimate of €1.071 by €0.03.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of €0.528 which represents an annual dividend yield of 5.01%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.26.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,036,473,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.101 in its last earnings report, beating expectations of €1.071. Following the earnings report the stock price went up 4.011%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in DE:BRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€54.58 (5.86% Upside)
€54.58 (5.86% Upside)
Blogger Sentiment
Bullish
DE:BRM Sentiment 92%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 79%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.96%
12-Months-Change
Fundamentals
Return on Equity
39.27%
Trailing 12-Months
Asset Growth
-2.77%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BRM Company Deck
BRM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all DE:BRM earnings summariesBRM Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BRM Stock 12 Month Forecast
Average Price Target
€54.58
▲(5.86% Upside)
Technical Analysis
Options Prices
Currently, No data available
---